ArticleInternational journal of molecular sciences2023
IL-6 and TGF-β-Secreting Adoptively-Transferred Murine Mesenchymal Stromal Cells Accelerate Healing of Psoriasis-like Skin Inflammation and Upregulate IL-17A and TGF-β.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Novel sponge formulation of mesenchymal stem cell secretome and hyaluronic acid: a safe and effective topical therapy for Psoriasis vulgaris.Stem cell research & therapy · 2025Trial
- Multi-Omics Analysis Identifies Fibroblast-Associated Stromal-Immune Networks Linked to Pregnancy-Associated Attenuation of Imiquimod-Induced Psoriatic Dermatitis.Biomedicines · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Secretome as a novel regenerative strategy for atopic dermatitis: a comprehensive review.Stem cell research & therapy · 2026Review
- Human urine-derived stem cells alleviate psoriasis by suppressing JAK2/STAT3 pathway-mediated macrophage polarization.Stem cell research & therapy · 2025Article
- Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways.Scientific reports · 2025Article
- Therapeutic Potential of Mesenchymal Stem Cells in Psoriasis.Cell biochemistry and biophysics · 2025Review
- The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects.International journal of molecular sciences · 2025Review
- Article
- The Secretome of Human Deciduous Tooth-Derived Mesenchymal Stem Cells Enhances In Vitro Wound Healing and Modulates Inflammation.Pharmaceutics · 2025Article
- Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics.Molecular biotechnology · 2025Article
- Immunomodulatory interactions between mesenchymal stromal/stem cells and immune cells in psoriasis: therapeutic potential and challenges.Stem cell research & therapy · 2025Review
- Review
- Interventions in cytokine signaling: novel horizons for psoriasis treatment.Frontiers in immunology · 2025Review
- Psoriasis: The Versatility of Mesenchymal Stem Cell and Exosome Therapies.Biomolecules · 2024Review
- Expert Consensus on the Application of Stem Cells in Psoriasis Research and Clinical Trials.Aging and disease · 2024Review
- IFN-γ-Preconditioned Human Gingival-Derived Mesenchymal Stromal Cells Inhibit Plasmacytoid Dendritic Cells via Adenosine.Biomolecules · 2024Article
- METTL14 promotes IL-6-induced viability, glycolysis and inflammation in HaCaT cells via the m6A modification of TRIM27.Journal of cellular and molecular medicine · 2024Article
- Pro-inflammatory cytokine IL-6 regulates LMO4 expression in psoriatic keratinocytes via AKT/STAT3 pathway.Immunity, inflammation and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Mesenchymal stromal cells (MSC) show promise as cellular therapeutics. Psoriasis is a chronic inflammatory disease affecting the skin and the joints. Injury, trauma, infection and medications can trigger psoriasis by disrupting epidermal keratinocyte proliferation and differentiation, which activates the innate immune system. Pro-inflammatory cytokine secretion drives a T helper 17 response and an imbalance of regulatory T cells. We hypothesized that MSC adoptive cellular therapy could immunomodulate and suppress the effector T cell hyperactivation that underlies the disease. We used the imiquimod-induced psoriasis-like skin inflammation model to study the therapeutic potential of bone marrow and adipose tissue-derived MSC in vivo. We compared the secretome and the in vivo therapeutic potential of MSC with and without cytokine pre-challenge ("licensing"). The infusion of both unlicensed and licensed MSC accelerated the healing of psoriatic lesions, and reduced epidermal thickness and CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.